Incidence and risk factors for invasive fungal infections in patients initiating TNF-alpha inhibitors for inflammatory bowel disease and rheumatoid arthritis.
Ian P HennesseeKaitlin BenedictNathan C BahrShari R LipnerJeremy A W GoldPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an IFI within one year of initiating TNF-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.
Keyphrases
- rheumatoid arthritis
- patients with inflammatory bowel disease
- disease activity
- end stage renal disease
- ejection fraction
- newly diagnosed
- interstitial lung disease
- peritoneal dialysis
- chronic kidney disease
- ankylosing spondylitis
- health insurance
- prognostic factors
- emergency department
- stem cells
- risk factors
- systemic lupus erythematosus
- systemic sclerosis
- patient reported outcomes
- bone marrow
- electronic health record
- patient reported